Categories
Change Password!
Reset Password!
Golimumab displayed good retention
rates at two years when used for treating people with axial spondyloarthritis
and rheumatoid arthritis.
In a real-world setting, golimumab is effective for managing rheumatoid arthritis and axial spondyloarthritis individuals with good retention rates at two years. This real-world study aimed to explore the retention rate of golimumab in individuals having rheumatoid arthritis and axial spondyloarthritis that had received/were receiving golimumab as their 1st or 2nd biological drug for at least three months.
Data on drug continuation and disease activity, and demographic and clinical data were collected. Participants were segregated as biologic-naive and biologic-experienced. The study incorporated 60 rheumatoid arthritis and 269 axial spondyloarthritis participants. At 24 months, the retention rate for rheumatoid arthritis patients (biologic-naive and biologic-experienced) and axial spondyloarthritis patients (Anti TNF-naive and -experienced) is illustrated in Table 1:
No vital differences in retention
rates were witnessed between the groups for either disease. Thus, golimumab is an effective therapeutic agent with good
retention rates for managing axial spondyloarthritis and rheumatoid arthritis
patients.
Immunotherapy
GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey
Servet Akar et al.
Comments (0)